312 related articles for article (PubMed ID: 35078191)
21. Response and relapse rates after treatment with long-acting somatostatin analogs in multifocal or recurrent type-1 gastric carcinoids: A systematic review and meta-analysis.
Rossi RE; Invernizzi P; Mazzaferro V; Massironi S
United European Gastroenterol J; 2020 Mar; 8(2):140-147. PubMed ID: 32213066
[TBL] [Abstract][Full Text] [Related]
22. Clinical impact of unsuccessful subcutaneous administration of octreotide LAR instead of intramuscular administration in patients with metastatic gastroenteropancreatic neuroendocrine tumors.
Krishnan T; Safro M; Furlanetto DM; Gill S; Solar Vasconcelos JP; Stuart HC; Martineau P; Loree JM
J Neuroendocrinol; 2024 Jan; 36(1):e13360. PubMed ID: 38088132
[TBL] [Abstract][Full Text] [Related]
23.
Satapathy S; Mittal BR; Sood A; Sood A; Kapoor R; Gupta R; Khosla D
JCO Glob Oncol; 2021 Jul; 7():1167-1175. PubMed ID: 34288699
[TBL] [Abstract][Full Text] [Related]
24. Therapeutic sequences in patients with grade 1-2 neuroendocrine tumors (NET): an observational multicenter study from the ELIOS group.
Faggiano A; Di Maio S; Mocerino C; Ottaviano M; De Divitiis C; Guarnotta V; Dolce P; Modica R; Puliafito I; Tozzi L; Di Sarno A; Leo S; Riccardi F; Palmieri G; Tafuto S; Bianco A; Badalamenti G; Colao A;
Endocrine; 2019 Nov; 66(2):417-424. PubMed ID: 30875056
[TBL] [Abstract][Full Text] [Related]
25. Everolimus in combination with octreotide long-acting repeatable in a first-line setting for patients with neuroendocrine tumors: an ITMO group study.
Bajetta E; Catena L; Fazio N; Pusceddu S; Biondani P; Blanco G; Ricci S; Aieta M; Pucci F; Valente M; Bianco N; Mauri CM; Spada F
Cancer; 2014 Aug; 120(16):2457-63. PubMed ID: 24752410
[TBL] [Abstract][Full Text] [Related]
26. Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-octreotate.
Ezziddin S; Attassi M; Yong-Hing CJ; Ahmadzadehfar H; Willinek W; Grünwald F; Guhlke S; Biersack HJ; Sabet A
J Nucl Med; 2014 Feb; 55(2):183-90. PubMed ID: 24434296
[TBL] [Abstract][Full Text] [Related]
27. Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3: a multicenter cohort study.
Carlsen EA; Fazio N; Granberg D; Grozinsky-Glasberg S; Ahmadzadehfar H; Grana CM; Zandee WT; Cwikla J; Walter MA; Oturai PS; Rinke A; Weaver A; Frilling A; Gritti S; Arveschoug AK; Meirovitz A; Knigge U; Sorbye H
Endocr Relat Cancer; 2019 Feb; 26(2):227-239. PubMed ID: 30540557
[TBL] [Abstract][Full Text] [Related]
28. Lanreotide for the treatment of gastroenteropancreatic neuroendocrine tumors.
Saif MW
Expert Opin Pharmacother; 2016; 17(3):443-56. PubMed ID: 26635177
[TBL] [Abstract][Full Text] [Related]
29. Escalated-dose somatostatin analogues for antiproliferative effect in GEPNETS: a systematic review.
Chan DL; Ferone D; Albertelli M; Pavlakis N; Segelov E; Singh S
Endocrine; 2017 Sep; 57(3):366-375. PubMed ID: 28726183
[TBL] [Abstract][Full Text] [Related]
30. Adjuvant therapy following resection of gastroenteropancreatic neuroendocrine tumors provides no recurrence or survival benefit.
Barrett JR; Rendell V; Pokrzywa C; Lopez-Aguiar AG; Cannon J; Poultsides GA; Rocha F; Crown A; Beal E; Michael Pawlik T; Fields R; Panni RZ; Smith P; Idrees K; Cho C; Beems M; Maithel S; Weber S; Erik Abbott D
J Surg Oncol; 2020 Jun; 121(7):1067-1073. PubMed ID: 32153032
[TBL] [Abstract][Full Text] [Related]
31. Somatostatin analogs in association with peptide receptor radionucleotide therapy in advanced well-differentiated NETs.
Prinzi N; Raimondi A; Maccauro M; Milione M; Garanzini E; Torchio M; Corti F; Nichetti F; Lo Russo G; Giacomelli L; Mazzaferro V; Di Bartolomeo M; Seregni E; de Braud F; Pusceddu S
Future Oncol; 2019 Sep; 15(26):3015-3024. PubMed ID: 31424273
[No Abstract] [Full Text] [Related]
32. Optimizing Somatostatin Analog Use in Well or Moderately Differentiated Gastroenteropancreatic Neuroendocrine Tumors.
Carmona-Bayonas A; Jiménez-Fonseca P; Custodio A; Grande E; Capdevila J; López C; Teule A; Garcia-Carbonero R;
Curr Oncol Rep; 2017 Sep; 19(11):72. PubMed ID: 28920153
[TBL] [Abstract][Full Text] [Related]
33. New and Emerging Treatment Options for Gastroenteropancreatic Neuroendocrine Tumors.
Phan AT; Kunz PL; Reidy-Lagunes DL
Clin Adv Hematol Oncol; 2015 May; 13(5 Suppl 5):1-18; quiz 1 p following 18. PubMed ID: 26430956
[TBL] [Abstract][Full Text] [Related]
34. Phase II clinical trial of pasireotide long-acting repeatable in patients with metastatic neuroendocrine tumors.
Cives M; Kunz PL; Morse B; Coppola D; Schell MJ; Campos T; Nguyen PT; Nandoskar P; Khandelwal V; Strosberg JR
Endocr Relat Cancer; 2015 Feb; 22(1):1-9. PubMed ID: 25376618
[TBL] [Abstract][Full Text] [Related]
35. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group.
Rinke A; Müller HH; Schade-Brittinger C; Klose KJ; Barth P; Wied M; Mayer C; Aminossadati B; Pape UF; Bläker M; Harder J; Arnold C; Gress T; Arnold R;
J Clin Oncol; 2009 Oct; 27(28):4656-63. PubMed ID: 19704057
[TBL] [Abstract][Full Text] [Related]
36. Treatment Patterns and Clinical Outcomes in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors Treated in the Community Practice Setting in the United States.
Jiao X; Pulgar S; Boyd M; Braiteh F; Mirakhur B; Pitman Lowenthal S; Fox P; Frytak J; Cox D; Paulson AS
Pancreas; 2018 Feb; 47(2):173-182. PubMed ID: 29206668
[TBL] [Abstract][Full Text] [Related]
37. Long-acting somatostatin analogues in the treatment of unresectable/metastatic neuroendocrine tumors.
Enzler T; Fojo T
Semin Oncol; 2017 Apr; 44(2):141-156. PubMed ID: 28923213
[TBL] [Abstract][Full Text] [Related]
38. Somatostatin analogs in pregnant patients with neuroendocrine tumor.
Meoni G; Giommoni E; Petreni P; Pillozzi S; Mazzoni F; Pellegrini E; Brugia M; Lunghi A; Muto A; Antonuzzo L
Anticancer Drugs; 2020 Nov; 31(10):1096-1098. PubMed ID: 32590392
[TBL] [Abstract][Full Text] [Related]
39. Targeted Therapy: New Radiolabeled Somatostatin Analogs to Treat Gastroenteropancreatic Neuroendocrine Tumors.
Boucher JE; Sommers R
Clin J Oncol Nurs; 2018 Oct; 22(5):565-568. PubMed ID: 30239510
[TBL] [Abstract][Full Text] [Related]
40. Lanreotide in metastatic enteropancreatic neuroendocrine tumors.
Caplin ME; Pavel M; Ćwikła JB; Phan AT; Raderer M; Sedláčková E; Cadiot G; Wolin EM; Capdevila J; Wall L; Rindi G; Langley A; Martinez S; Blumberg J; Ruszniewski P;
N Engl J Med; 2014 Jul; 371(3):224-33. PubMed ID: 25014687
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
